8-K: Windtree Therapeutics Announces Positive Phase 2b Results for Istaroxime in Heart Failure Patients

Windtree Therapeutics reports positive topline results from its Phase 2b SEISMiC Extension Study, showing istaroxime significantly improved cardiac function and blood pressure in heart failure patients experiencing early cardiogenic shock.

Summary

• Windtree Therapeutics announced positive results from its Phase 2b SEISMiC Extension Study of istaroxime in heart failure patients with early cardiogenic shock.
• The study, which included 30 patients, evaluated istaroxime's ability to improve blood pressure, cardiac function, and other parameters over 96 hours.
• The primary endpoint of significantly improving systolic blood pressure over six hours was met, with the istaroxime group showing a significantly better result compared to the placebo group (62.07 vs 36.47 mmHg*hr, p = 0.0070).
• The study also showed significant improvements in systolic blood pressure at 24, 48 and 60 hours.
• Cardiac output improved by approximately 15% in the istaroxime group during the infusion.
• The study also showed statistically significant reductions in heart rate at 12 and 24 hours in the istaroxime group.
• Pulmonary capillary wedge pressure was significantly reduced in the istaroxime group compared to placebo within six hours (-6.6 vs -0.9 mmHg, p = 0.0001).
• Mixed venous oxygen saturation was significantly improved by 12 hours in the istaroxime group compared to placebo (approximately 9%, p=0.0071).
• Renal function, measured by estimated glomerular filtration rate, was improved in the istaroxime group compared to placebo, reaching statistical significance at 48 hours (p =0.0291).
• The New York Heart Association classification of heart failure severity significantly decreased in the istaroxime group at 24, 48, and 72 hours.
• Worsening heart failure as a serious adverse event occurred less frequently in the istaroxime group compared to placebo (5.3% versus 18.2%).
• The safety profile of istaroxime was generally consistent with previous trials, with treatment-emergent adverse events reported more frequently in the istaroxime group, mainly due to nausea, vomiting, infusion site discomfort and headache.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, indicating a potential breakthrough in treating cardiogenic shock. The positive data is tempered by the mention of potential risks and the need for further development, but the overall tone is optimistic.

Positives

• Istaroxime demonstrated a statistically significant improvement in systolic blood pressure compared to placebo.
• The study showed a 15% improvement in cardiac output during istaroxime infusion.
• Istaroxime treatment led to a significant reduction in pulmonary capillary wedge pressure.
• Mixed venous oxygen saturation was significantly improved with istaroxime treatment.
• Renal function, as measured by eGFR, improved in the istaroxime group.
• The New York Heart Association classification of heart failure severity improved with istaroxime treatment.
• Worsening heart failure as a serious adverse event was less frequent in the istaroxime group.

Negatives

• Treatment-emergent adverse events were more frequent in the istaroxime group (78.9%) compared to the placebo group (45.5%), primarily due to nausea, vomiting, infusion site discomfort and headache.
• Serious adverse events occurred in 10.5% of the istaroxime group and 27.3% of the placebo group.

Risks

• The company's ability to secure additional capital is a risk.
• There are risks associated with the success and advancement of clinical development programs for istaroxime and other product candidates.
• The company faces risks related to technology transfers to contract manufacturers and manufacturing development activities.
• Delays in manufacturing drug products, drug substances, and other materials could impact the company.
• Regulatory approvals may be delayed or not granted.
• The company may not realize the value of its intangible assets.
• There are risks related to the size and growth potential of the markets for the company's product candidates.
• The company's ability to develop sales and marketing capabilities is a risk.
• The rate and degree of market acceptance of the company's product candidates is a risk.
• Economic and social consequences of the COVID-19 pandemic and political unrest could have an adverse impact on the company's operations.

Future Outlook

The company is planning to pursue the next steps of development for istaroxime, potentially leading to a late-stage Phase 3 clinical trial.

Management Comments

• Alexandre Mebazaa, MD, PhD, FESC, stated that istaroxime has a unique profile and may be the only drug candidate that has been shown to simultaneously improve blood pressure, cardiac output and renal function without increasing heart rate or risk for cardiac arrhythmias.
• Craig Fraser, CEO and Chairman of Windtree Therapeutics, said they are very pleased with the results of the SEISMiC cardiogenic shock study and are excited to pursue the next steps of development.

Industry Context

The announcement is significant as it highlights a potential new treatment option for heart failure patients experiencing early cardiogenic shock, a condition with high morbidity and mortality. The positive results could position Windtree as a key player in the development of therapies for this critical condition.

Comparison to Industry Standards

• The results of the istaroxime trial are promising when compared to existing treatments for cardiogenic shock, which often struggle to improve both blood pressure and cardiac output without adverse effects on heart rate or rhythm.
• Many current treatments for cardiogenic shock focus on either increasing blood pressure or improving cardiac output, but istaroxime appears to address both simultaneously, which is a significant advantage.
• The improvement in renal function is also notable, as kidney dysfunction is a common complication of cardiogenic shock and can worsen patient outcomes.
• The fact that istaroxime did not increase clinically significant arrhythmias is a key differentiator from some other inotropic agents used in heart failure.

Stakeholder Impact

• Shareholders may react positively to the positive clinical trial results.
• Patients with heart failure and cardiogenic shock may benefit from the potential development of istaroxime.
• Employees of Windtree Therapeutics may be motivated by the positive results and the potential for future success.

Next Steps

• The company plans to pursue the next steps of development for istaroxime.
• The company is planning a Virtual Investor Day presentation on October 1st to discuss the results and forward-looking strategy.

Key Dates

Keywords

Istaroxime, Heart Failure, Cardiogenic Shock, Clinical Trial, Phase 2b, Systolic Blood Pressure, Cardiac Output, Renal Function, SEISMiC Study, Windtree Therapeutics